Revasum Gets Closer to IPO
Listing on ASX Imminent
SAN LUIS OBISPO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Revasum (the “Company” or “Revasum”), a growing semiconductor equipment manufacturer, today lodged a prospectus with the Australian Securities and Investment Commission (“ASIC”) for its initial public offering “(IPO”) and applied to the Australian Securities Exchange (“ASX”) for the listing of its shares (in the form of CHESS Depositary Interests or CDIs) under the code ASX:RVS. The offer to raise A$30.7 million before fees, is fully underwritten at an offer price of A$2.00 per share. Moelis Australia Advisory Pty Ltd and Shaw and Partners Limited will act as Joint Lead Managers and Underwriters, to the IPO.
Revasum designs and manufactures the equipment needed to power our modern world. Every year, our devices get smarter and smaller. This trend is only possible because of technology called CMP (Chemical Mechanical Planarization) and Grinding, which are used in the semiconductor device manufacturing process. Semiconductors are a key component in almost all modern electronics, including various kinds of communication, mobile phones, computing, internet of things (IoT) enabled devices and automotive components.
“We are thrilled that Revasum’s IPO on the Australian Securities Exchange is generating excitement,” said Jerry Cutini, CEO of Revasum. “It has been an exciting journey working towards the completion of the IPO process and the imminent listing of Revasum on the ASX is a crucial next step for the Company. Revasum is developing new semiconductor equipment technology and the IPO will allow the business to expand into new global markets and capitalize on new opportunities.”
Growth in the global semiconductor market is primarily driven by the growth in end-use markets including computing, communications, automotive, IoT and mobile phones. IC Insights forecasts growth in the semiconductor market to continue over the next five years to US$570 billion of revenue in 2022, representing a CAGR of 5.4%.
Revasum will use funds raised under the IPO to invest in new product development and capital projects and fund expansion including sales and marketing activities, while the ASX listing will enhance Revasum’s profile by becoming a listed company.
The IPO is expected to close at the end of November of this year and the CDIs will be tradeable in early December upon the ASX approving Revasum’s listing.
Revasum designs, manufactures and markets a portfolio of semiconductor equipment. Our product portfolio includes grinding, polishing, and chemical mechanical planarization equipment (also referred to as “systems”) used to manufacture substrates and devices for the global semiconductor industry.
The systems that we manufacture are a key part of the production chain in manufacturing and processing wafers sized 200mm and below that are used to make microchips, sensors, LEDs, RF devices and power devices which are commonly used in connected “Internet of Things” devices, smart phones, wearables, automotive sensors, 5G and industrial applications. Our customers are the leading technology providers to these end markets.
Revasum is headquartered in San Luis Obispo, California, United States, and has direct, independent sales and service offices located worldwide.
The offer will be made under the Prospectus, which is available at www.revasum.com. Any person who wishes to acquire CDIs should consider the Prospectus in full and submit the application form which will be in or accompany the Prospectus. There will be no general public offer of shares under the Prospectus.
The Prospectus does not constitute an offer or invitation to apply for CDIs in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the CDIs or the IPO or to otherwise permit a public offering of the CDIs, in any jurisdiction outside Australia. Neither the Shares nor the CDIs have been registered in the United States, and may not be sold or offered in the United States. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction where such offer, solicitation or sale would be unlawful.
For press inquiries contact Thea Davis at (805) 541-6424